Osteoporosis is a highly prevalent bone disease afecting more than 37.5 million individuals in the European Union (EU)<br/>and the United States of America (USA). It is characterized by low bone mineral density (BMD), impaired bone quality, and<br/>loss of structural and biomechanical properties, resulting in reduced bone strength. An increase in morbidity and mortality<br/>is seen in patients with osteoporosis, caused by the approximately 3.5 million new osteoporotic fractures occurring every<br/>year in the EU. Currently, diferent medications are available for the treatment of osteoporosis, including anti-resorptive and<br/>osteoanabolic medications. Bisphosphonates, which belong to the anti-resorptive medications, are the standard treatment for<br/>osteoporosis based on their positive efects on bone, long-term experience, and low costs. However, not only medications used<br/>for the treatment of osteoporosis can afect bone: several other medications are suggested to have an efect on bone as well,<br/>especially on fracture risk and BMD. Knowledge about the positive and negative efects of diferent medications on both fracture risk and BMD is important, as it can contribute to an improvement in osteoporosis prevention and treatment in general,<br/>and, even more importantly, to the individual’s health. In this review, we therefore discuss the efects of both osteoporotic<br/>and non-osteoporotic medications on fracture risk and BMD. In addition, we discuss the underlying mechanisms of action.<br/>

doi.org/10.1007/s40265-021-01625-8, hdl.handle.net/1765/137127
Drugs
Erasmus MC: University Medical Center Rotterdam

A.C. (Lisa) van der Burgh, C.E. (Toke) de Keyser, M.C. Zillikens, & B.H.C. (Bruno) Stricker. (2021). The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density. Drugs (Vol. 81, pp. 1831–1858). doi:10.1007/s40265-021-01625-8